Market Analysis
Novo Nordisk (NVO) Shares Fall on Unexpected 2026 Sales Outlook
Novo Nordisk shares tumbled 18% after the company issued unexpectedly weak 2026 guidance, forecasting sales could decline as much as 13%.
Total Stories
7
News
Novo Nordisk
Section
Novo Nordisk
Market Analysis
Novo Nordisk Shares Rise After FDA Pressures Hims to Pull Weight-Loss Pill
Novo Nordisk stock jumped 8% after Hims & Hers withdrew its knockoff Wegovy pill amid FDA scrutiny and legal threats.
Market Analysis
Why Is Novo Nordisk Stock Popping in Premarket? Wegovy Pill Wins FDA Approval
Novo Nordisk shares rose more than 7% in premarket trading after the FDA approved its oral Wegovy weight-loss pill.
Market Analysis
Why did Novo Nordisk’s Stock Crash Over 20% in Premarket Trading Today?
Novo Nordisk stock crashed over 20% in premarket trading after the company cut its 2025 forecast for the second time.
Market Analysis
Novo Nordisk’s Shares Dip Amid Surprise CEO Exit in Challenging Times for the Firm
Novo Nordisk's surprise CEO departure amid mounting competitive pressures and disappointing clinical results has accelerated the stock's 50% decline since mid-2024.
Market Analysis
The Weight Loss Market Can Surge to $400 B by 2032, and these Stocks Will Rule it
Despite Novo Nordisk's momentum, Eli Lilly seems a better long-term bet. Pfizer could surprise everyone from an undervalued position.
Best Stocks
LLY vs NVO: Which One is Likely to Become a $1T Company First
Tackling growing waistlines is expected to yield much shareholder value.